Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEEQUOIA-AHF: Sequential Nephron Blockade in Acute Heart Failure
NCT04062760Phase 4Unknown
- Sponsor
- University of Parma
- Start
- Dec 2019
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of metolazone and acetazolamide in Acute Heart Failure (AHF) (2 arms), sponsored by University of Parma. Primary endpoints: Body weight change at 96 hours since randomization and Serum creatinine change at 96 hours since randomization. Status: unknown.
02
Drugs
metolazoneacetazolamide
03
Conditions
Acute Heart Failure (AHF)
Beyond the preview
Go deeper on NCT04062760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04062760.